PMID- 15334863
OWN - NLM
STAT- MEDLINE
DCOM- 20041104
LR  - 20190917
IS  - 0277-0008 (Print)
IS  - 0277-0008 (Linking)
VI  - 24
IP  - 8 Pt 2
DP  - 2004 Aug
TI  - Economics of unfractionated heparin: beyond acquisition cost.
PG  - 161S-164S
AB  - Despite numerous clinical trials demonstrating advantages of new anticoagulants, 
      unfractionated heparin (UFH) is still used by a number of clinicians in the 
      United States. The reason for this continued use of UFH is not superior efficacy, 
      improved safety, or convenience, but low acquisition cost. However, several other 
      costs associated with the use of UFH are often not considered. Appropriate 
      economic analysis, which considers both cost and outcomes, has not demonstrated 
      support for continued use of UFH. Its continued use based simply on lower cost is 
      not justified by the literature.
FAU - Dobesh, Paul P
AU  - Dobesh PP
AD  - Division of Pharmacy Practice, St Louis College of Pharmacy, and the Department 
      of Pharmacy, St Luke's Hospital, St Louis, Missouri 63110, USA. 
      pdobesh@stlcop.edu
CN  - Heparin Consensus Group
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Pharmacotherapy
JT  - Pharmacotherapy
JID - 8111305
RN  - 0 (Fibrinolytic Agents)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Fibrinolytic Agents/*economics/therapeutic use
MH  - Heparin/*economics/therapeutic use
MH  - Venous Thrombosis/*economics/prevention & control
RF  - 26
EDAT- 2004/09/01 05:00
MHDA- 2004/11/05 09:00
CRDT- 2004/09/01 05:00
PHST- 2004/09/01 05:00 [pubmed]
PHST- 2004/11/05 09:00 [medline]
PHST- 2004/09/01 05:00 [entrez]
AID - 10.1592/phco.24.12.161s.36108 [doi]
PST - ppublish
SO  - Pharmacotherapy. 2004 Aug;24(8 Pt 2):161S-164S. doi: 
      10.1592/phco.24.12.161s.36108.